These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Withdrawal of maintenance dialysis in a patient with diagnosed multiple myeloma and renal failure as a consequence of effective anti-tumor treatment]. Rosa J; Sydor A; Jurczyszyn A; Zabawa-Hołyś S; Nowak J; Czapkowicz-Gryszkiewicz L; Sułowicz W Przegl Lek; 2010; 67(7):547-50. PubMed ID: 21387773 [TBL] [Abstract][Full Text] [Related]
5. Management options for cast nephropathy in multiple myeloma. Cockwell P; Hutchison CA Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):550-5. PubMed ID: 20827195 [TBL] [Abstract][Full Text] [Related]
6. Impact of free light chain hemodialysis in myeloma cast nephropathy: a case-control study. Peters NO; Laurain E; Cridlig J; Hulin C; Cao-Huu T; Frimat L Hemodial Int; 2011 Oct; 15(4):538-45. PubMed ID: 22111823 [TBL] [Abstract][Full Text] [Related]
8. Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney. Basnayake K; Cheung CK; Sheaff M; Fuggle W; Kamel D; Nakoinz S; Hutchison CA; Cook M; Stoves J; Bradwell AR; Cockwell P J Clin Pathol; 2010 Oct; 63(10):884-7. PubMed ID: 20876319 [TBL] [Abstract][Full Text] [Related]
9. Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology. Fabbrini P; Finkel K; Gallieni M; Capasso G; Cavo M; Santoro A; Pasquali S J Nephrol; 2016 Dec; 29(6):735-746. PubMed ID: 27757797 [TBL] [Abstract][Full Text] [Related]
10. Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience. Borrego-Hinojosa J; Pérez-del Barrio MP; Biechy-Baldan Mdel M; Merino-García E; Sánchez-Perales MC; García-Cortés MJ; Ocaña-Pérez E; Gutiérrez-Rivas P; Liébana-Cañada A Nefrologia; 2013; 33(4):515-23. PubMed ID: 23897183 [TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Hutchison CA; Heyne N; Airia P; Schindler R; Zickler D; Cook M; Cockwell P; Grima D Nephrol Dial Transplant; 2012 Oct; 27(10):3823-8. PubMed ID: 22273664 [TBL] [Abstract][Full Text] [Related]
12. Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma: a meta-analysis. Yu X; Gan L; Wang Z; Dong B; Chen X Int J Clin Pharmacol Ther; 2015 May; 53(5):391-7. PubMed ID: 25816886 [TBL] [Abstract][Full Text] [Related]
13. Recovery of kidney function following delayed use of Theralite™ dialyzer in a patient with myeloma cast nephropathy. Dahal K; Shastri S; Narayanasami U; Bijol V; Rider K; Strom JA; Jaber BL Clin Nephrol; 2013 Apr; 79(4):318-22. PubMed ID: 22541683 [TBL] [Abstract][Full Text] [Related]
14. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney. Cockwell P; Cook M Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy. Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542 [TBL] [Abstract][Full Text] [Related]